About This Calculator

The Iressa (gefitinib) Dose Calculator is a clinical tool designed to assist healthcare professionals in determining the appropriate dosing schedule for patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It provides recommendations based on standard guidelines, adverse reactions, special patient populations, and potential drug interactions, aligning with the official prescribing information.

Outputs Explained

The calculator provides tailored dosing recommendations based on the selected clinical scenario. Key outputs include:

• Standard Dose: The recommended starting dose for eligible patients.
• Adverse Reaction Adjustments: Guidance on dose interruption or permanent discontinuation for toxicities such as interstitial lung disease (ILD), hepatotoxicity, diarrhea, and skin reactions.
• Special Populations: Dosing considerations for patients with hepatic or renal impairment.
• Drug Interaction Dosing: Recommended dose adjustments when co-administering with strong CYP3A4 inducers or guidance for monitoring with CYP3A4 inhibitors and gastric pH-modifying agents.

How to Use the Calculator

To use the tool effectively, follow these steps:

1. Select Calculation Type: Choose the clinical scenario that best fits your patient (e.g., Standard Dose, Adverse Reaction, Drug Interaction).
2. Provide Specifics: If you select a scenario other than "Standard Dose," additional fields will appear. For example, for an adverse reaction, you must specify the type of reaction and its CTCAE grade.
3. Calculate: Click the "Calculate" button to generate the dosing recommendation.
4. Review Results: The output will display the recommended dose, any necessary actions (like dose interruption), and important notes based on the provided information.

Dosing Overview

The standard oral dose of Iressa is 250 mg once daily, with or without food. However, this administration schedule may require modification based on individual patient factors.

• Adverse Reactions: For severe (Grade 3/4) toxicities, treatment is typically interrupted for up to 14 days. If the toxicity resolves to Grade 0-1, treatment can be resumed at the 250 mg dose. Interstitial Lung Disease (ILD) or severe hepatotoxicity warrants permanent discontinuation.
• Drug Interactions: Concomitant use with a strong CYP3A4 inducer (like rifampicin) may require increasing the Iressa dose to 500 mg daily. Close monitoring is advised when used with strong CYP3A4 inhibitors.
• Impairment: No dose adjustment is needed for renal impairment or mild-to-moderate hepatic impairment. Patients with severe hepatic impairment should be monitored closely.

Switching Therapies

There are no specific guidelines for switching to or from Iressa. Clinical judgment should guide the transition between different cancer therapies. When starting Iressa after another treatment, ensure any toxicities from the previous therapy have resolved. Gefitinib is an oral, once-daily therapy, which may offer a different administration profile compared to intravenous chemotherapy or other targeted agents.

Missed Dose

If a patient misses a dose of Iressa, they should take it as soon as they remember. However, if the next scheduled dose is due within 12 hours, the patient should skip the missed dose and take the next dose at the regular time. Patients should not take two doses at the same time to make up for a missed one.

Safety Alerts

Iressa has several important warnings and precautions. The most critical safety alerts requiring immediate clinical attention include:

• Interstitial Lung Disease (ILD): Potentially fatal ILD can occur. Patients presenting with new or worsening dyspnea, cough, and fever should be evaluated for ILD, and Iressa should be permanently discontinued if ILD is diagnosed.
• Hepatotoxicity: Severe and sometimes fatal hepatotoxicity has been reported. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be monitored periodically. For Grade 3-4 liver test abnormalities, Iressa should be permanently discontinued.
• Gastrointestinal Perforation: This has been observed in clinical trials. Patients should be advised to seek immediate medical care for severe abdominal pain.

Frequently Asked Questions

What is the Iressa dose adjustment for a patient on rifampicin?

Rifampicin is a strong CYP3A4 inducer. If co-administration is unavoidable, the recommended Iressa dose should be increased to 500 mg once daily. The dose should be returned to 250 mg daily 7 days after discontinuing the rifampicin.

Does Iressa require a dose change for patients with severe kidney disease?

No, a dose adjustment is not required for patients with severe renal impairment, including those with a creatinine clearance (CrCl) of less than 20 mL/min.

How should a Grade 3 skin rash be managed?

For a Grade 3 skin reaction (acneiform dermatitis), Iressa should be interrupted for up to 14 days. Once the toxicity resolves to Grade 0 or 1, treatment can be resumed at the standard 250 mg daily dose.

Can Iressa be taken with proton pump inhibitors (PPIs) like omeprazole?

Drugs that cause a sustained increase in gastric pH, such as PPIs, may reduce the plasma concentration of gefitinib and decrease its effectiveness. Concomitant use should be avoided if possible.

What is the recommendation for confirmed Interstitial Lung Disease (ILD)?

If a patient is diagnosed with Iressa-induced ILD, the medication must be permanently discontinued.

Is a dose adjustment needed for mild or moderate liver problems?

No dose adjustment is recommended for patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. However, these patients should be monitored for adverse reactions.

What if a patient develops Grade 2 diarrhea that won't go away?

For persistent Grade 2 diarrhea, treatment with Iressa should be interrupted for up to 14 days. It can be resumed at 250 mg daily once the diarrhea resolves to Grade 0-1. If it does not resolve, discontinuation should be considered.

Does Iressa have interactions with ketoconazole?

Yes, ketoconazole is a strong CYP3A4 inhibitor and can increase exposure to gefitinib. While no specific dose adjustment is mandated, patients should be monitored closely for adverse reactions if co-administration is necessary.

References

1. IRESSA® (gefitinib) tablets Prescribing Information. U.S. Food and Drug Administration. AstraZeneca Pharmaceuticals LP.
2. Iressa (gefitinib) for Healthcare Professionals. AstraZeneca USA.
3. Iressa (gefitinib) European Public Assessment Report (EPAR). European Medicines Agency.
4. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. doi:10.1056/nejmoa0909530
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2023. (Requires login)